ArticleScientific reports2025
Factors associated with patency following drug-coated balloon angioplasty of hemodialysis access.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors influencing patency after percutaneous transluminal angioplasty for autogenous arteriovenous fistulae: a systematic review and meta-analysis.Renal failure · 2026Pooled it
- Expression of Chitosanase-3-like Protein 1 in Outflow Tract Veins of Patients with Autologous Arteriovenous Fistula Failure and Potential Involvement with Phenotypic Transformation of Medial Smooth Muscle Cells.Applied biochemistry and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The purpose of this study was to determine predictors of hemodialysis access patency after drug-coated balloon angioplasty (DCBA) in patients with arteriovenous fistula (AVF). The clinical and imaging data of patients with hemodialysis access dysfunction treated with drug-coated balloon (DCB) in our hospital from January 2020 to January 2024 were analyzed retrospectively, the patency of hemodialysis access was followed up. The length of the DCB is 4 cm. Kaplan-Meier analysis was performed for determination of primary patency and secondary patency in this population. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify predictors of primary patency after DCBA. A total of 173 hemodialysis patients treated with DCB were included in the study. The median survival time of primary and secondary patency were 443 and 1035 days, and the primary patency rates at 6, 12, 18, 24, 30 and 36 months were 85.9%, 64.1%, 34.1%, 21.3%, 12.0% and 6.0%, respectively. The secondary patency rates at 6, 12, 18, 24, 30 and 36 months were 98.8%, 93.8%, 89.8%, 81.9%, 76.1% and 48.6%, respectively. Multivariate analysis using Cox proportional hazard regression models showed that lesion length>4 cm(p=0.002), tandem stenosis(p=0.007) and thrombosis (p < 0.001) were independent risk factors for primary patency after DCBA in patients with AVF. However, lesion length (p=0.021), residual stenosis (p=0.022), and thrombosis (p=0.018) were the independent predictors of primary patency in patients with single lesions.Lesion length>4 cm, tandem stenosis and thrombosis were found to be predictors of primary patency after using 4 cm length DCB. However, in patients with single lesions, lesion length, residual stenosis, and thrombosis serve as independent predictors of primary patency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.